Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy

AIDS

Volumn 27, Issue 10, 2013, Pages 1593-1602

  Taiwo, Babafemi ^a   Yanik, Elizabeth L ^b   Napravnik, Sonia ^b   Ryscavage, Patrick ^c   Koletar, Susan L ^d   Moore, Richard ^e   Mathews, W Christopher ^f   Crane, Heidi M ^g   Mayer, Kenneth ^h   Zinski, Anne ⁱ   Kahn, James S ^j   Eron, Joseph J ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; EFAVIRENZ; FOSAMPRENAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMBINATION ANTIRETROVIRAL THERAPY; DISEASE ASSOCIATION; DRUG COMBINATION; DRUG MONITORING; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; KIDNEY DISEASE; LABORATORY TEST; LIPID ANALYSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK; RISK STRATIFICATION; SIDE EFFECT; TREATMENT DURATION; UNITED STATES; CHEMICALLY INDUCED; DRUG-INDUCED LIVER INJURY; DYSLIPIDEMIAS; HEMATOLOGIC DISEASES; HIV INFECTIONS; INCIDENCE; KIDNEY DISEASES; MIDDLE AGED; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HEPATITIS B; HIV INFECTIONS; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84879115646     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283601115     Document Type: Article

References (35)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 27 March 2012. pp. 1-240. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf [Accessed 29 March 2012].
2. Bassett IV, Farel C, Szmuilowicz ED, Walensky RP. HIV/AIDS: AIDS Drug Assistance Programs in the era of routine HIV testing. Clin Infect Dis 2008; 47:695-701.
3. Snyder L, American College of Physicians Ethics, Professionalism, and Human Rights Committee. American College of Physicians Ethics Manual. 6th ed. Ann Intern Med 2012; 156:73-104.
4. Centers for Disease Control. HIV surveillance - United States, 1981-2008. MMWR 2011; 60:689-693.
5. The White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States. Washington DC: White House; 2010. http://aids.gov/federal-resources/national-hiv-aids-strategy/nhas.pdf. [Accessed 1 September 2012].
6. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 Recommendations of the International Antiviral Society-USA Panel. JAMA 2012; 308:387-402.
7. Koenig SP, Schackman BR, Riviere C, Leger P, Charles M, Severe P, et al. Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving anti-retroviral therapy in a resource-poor setting. Clin Infect Dis 2010; 51:600-608.
8. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised noninferiority trial. Lancet 2010; 375:123-131.
9. Blanco JR, Caro AM, Pérez-Cachafeiro S, Gutiérrez F, Iribarren JA, González-García J, et al. HIV infection and aging. AIDS Rev 2010; 12:218-230.
10. Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V, et al. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med 2011; 12:4-13.
11. Towner WJ, Xu L, Leyden WA, Horberg MA, Chao CR, Tang B, et al. The effect of HIV infection, immunodeficiency and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr 2012; 60:321-327.
12. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
13. 3 in Mexico. J Acquir Immune Defic Syndr 2010; 53:582-588.
14. Kitahata MM, Rodriguez B, Haubrich R, Boswell S, Mathews WC. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol 2008; 37:948-955.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130:461-470.
16. Hernan MA, McAdams M, McGrath N, Lanoy E, Costagliola D. Observation plans in longitudinal studies with time-varying treatments. Stat Methods Med Res 2009; 18:27-52.
17. Hernan MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol 2006; 98:237-242.
18. Macías J, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, et al. Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one nonnucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients. HIV Clin Trials 2012; 13:61-69.
19. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, et al. Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21:1119-1127.
20. Moyer VA. Screening for chronic kidney disease: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 20128. http://annals.org/ article.aspx?articleID=1355168. [Accessed 6 September 2012].
21. Rachlis A, Fanning MM. Zidovudine toxicity. Clinical features and management. Drug Saf 1993; 8:312-320.
22. Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, Vlahov D. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and uninfected women. Clin Infect Dis 2002; 34:260-266.
23. Judy HE, Price NB. Hemoglobin level and red blood cell count findings in normal women. JAMA 1958; 167:563-566.
24. Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 1999; 133:15-22.
25. Crane HM, Grunfeld C, Willig JH, Mugavero MJ, Van Rompaey S, Moore R, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 2011; 25:185-195.
26. Longenecker CT, Scherzer R, Bacchetti P, Lewis CE, Grunfeld C, Shlipak MG. HIV viremia and changes in kidney function. AIDS 2009; 23:1089-1096.
27. O'Donnell EP, Scarsi KK, Darin KM, Gerzenshtein L, Postelnick MJ, Palella FJ. Low incidence of renal impairment observed in tenofovir-treated patients. J Antimicrob Chemother 2011; 66:1120-1126.
28. Scherzer R, Estrella M, Li Y, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26:867-875.
29. Calza L, Trapani F, Tedeschi S, Piergentili B, Manfredi R, Colangeli V, et al. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients. Scand J Infect Dis 2011; 43:656-660.
30. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, et al. Impact of tenofovir on renal function in HIV infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010; 53:62-69.
31. Gallant JE, Moore RD. Renal function with use of a tenofovircontaining initial antiretroviral regimen. AIDS 2009; 23:1971-1975.
32. Davidson MH. Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. Arterioscler Thromb Vasc Biol 2008; 28:1582.
33. Marks G, Gardner LI, Craw J, Crepaz N. Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. AIDS 2010; 24:2665-2678.
34. Radford MJ, Foody JM. How do observational studies expand the evidence base for therapy? JAMA 2001; 286:1228-1230.
35. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010; 15:413-423.